(19)
(11) EP 4 816 366 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24827495.3

(22) Date of filing: 26.11.2024
(51) International Patent Classification (IPC): 
C07D 403/14(2006.01)
A61K 31/498(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 403/14; A61P 35/00
(86) International application number:
PCT/US2024/057468
(87) International publication number:
WO 2025/117550 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 01.12.2023 US 202363604977 P

(71) Applicant: Black Diamond Therapeutics, Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • KUMAR, Santosh
    Lexington, Massachusetts 02420 (US)
  • MOSHOS, Kristos Adrian
    Belmont, Massachusetts 02478 (US)

(74) Representative: Schlich 
9 St Catherine's Road Littlehampton
West Sussex BN17 5HS
West Sussex BN17 5HS (GB)

   


(54) SOLID STATE FORMS OF A QUINOXALINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER